Chicago Capital LLC Buys 3,865 Shares of Johnson & Johnson $JNJ

Key Points

• Chicago Capital LLC increased its stake in Johnson & Johnson by 6.3% during the second quarter, acquiring an additional 3,865 shares for a total of 65,512 shares worth approximately $10 million.
• Several analysts have raised their price targets for Johnson & Johnson, with JPMorgan setting a new target of $200.00, while Guggenheim upgraded the stock from neutral to buy and raised their target to $206.00.
• Johnson & Johnson's recent quarterly earnings report showed an EPS of $2.77, surpassing expectations and reflecting a 5.8% year-over-year revenue growth.

Chicago Capital LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.3% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 65,512 shares of the company's stock after acquiring an additional 3,865 shares during the quarter. Chicago Capital LLC's holdings in Johnson & Johnson were worth $10,007,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Highline Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on JNJ. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. UBS Group upped their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. The Goldman Sachs Group upped their price objective on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research report on Friday, September 19th. Finally, Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Price Performance

Shares of JNJ opened at $185.99 on Thursday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $186.56. The business has a 50-day simple moving average of $175.45 and a two-hundred day simple moving average of $162.51. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $447.92 billion, a PE ratio of 19.89, a PEG ratio of 2.36 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.